Pan-Europe

Pan-European One Health Network to strengthen infectious disease response

A new pan-European network will launch in October 2026 to improve how Europe detects, monitors, and prevents infectious disease threats, after the Infection Innovation Consortium (iiCON) secured funding from the European Cooperation in Science and Technology to establish the initiative. The Pan European One Health Network for Infectious Diseases Detection, Monitoring and Prevention will bring together more than 70 collaborators from 21 countries and international organisations to harmonise infectious disease response across Europe. The network aims to develop coordinated, preventative appro...

ACC issues decision pathway for postpartum cardiovascular care

A new Expert Consensus Decision Pathway by the American College of Cardiology (ACC) provides recommended strategies for improving postpartum care for individuals with and at risk for short- and long-term cardiovascular disease (CVD).  The clinical...

Prior myocardial infarction linked to faster cognitive decline

A decade-long analysis of more than 20,000 participants in the REGARDS cohort found that prior myocardial infarction (MI) -- including clinically silent MIs detected only by ECG -- was linked to significantly faster rates of cognitive decline over ti...


Sixty Seconds Science


Spotify episodes

Apple podcasts

Google podcasts

Partner

Search:
Date
Filters:
The Benefi...
12:28

The Benefits of Glucagon/GLP-1 Receptor Dual Agonism: Insights from the SYNCHRONIZE™ Phase 3 Studies of Survodutide

Presenter: Carel Le Roux
Diabetology
ADA 2026
Lymphoma H
11:55

Lymphoma Highlights and Key Takeaways from the 2026 ASCO Annual Meeting

Presenter: Joshua Brody
Oncology
ASCO 2026
The CAPIte...
25:30

The CAPItello-291 Trial: Final Overall Survival Results of Capivasertib and Fulvestrant in HR+/HER2− Advanced Breast Cancer

Presenter: Hope Rugo
Oncology : Breast Cancer
ESMO BC 2026
Immunother
12:02

Immunotherapy in Early-Stage Breast Cancer - Report from ESMO BC 2026

Presenter: Giampaolo Bianchini
Oncology : Breast Cancer
ESMO BC 2026
Highlights
9:44

Highlights and key takeaways from the 2026 EPA Congress

Presenter: Meryam Schouler-Ocak
Psychiatry
EPA 2026
Therapeuti
7:55

Therapeutic Novelties in the New ACC 2026 Acute Pulmonary Embolism Guideline

Presenter: Geoffrey D. Barnes
Cardiology
ACC 2026
Efficacy a
4:25

Efficacy and Safety of Sotatercept in PH-HFpEF: Results From the Phase 2 CADENCE Trial

Presenter: Mardi Gomberg-Maitland
Cardiology
ACC 2026
The INSIS
8:01

The INSIS Metacohort Vaccine Safety Study: A Paradigm for Clinical and Immune AEFI Profiling

Presenter: Asimenia Angelidou
Internal Medicine
WVCDC 2026
Human Chal
11:07

Human Challenge Models: A New Gold Standard?

Presenter: Stephen Thomas
Internal Medicine
WVCDC 2026
Combining
6:33

Combining Respiratory Vaccines - Balancing Efficacy, Durability and Immunization Schedules

Presenter: Bill Hausdorff
Internal Medicine
WVCDC 2026
Prove it's
3:05

Prove it's safe: Is this the new vaccine policy "norm?"

Presenter: Richard Hughes IV
Internal Medicine
WVCDC 2026
Building a
4:00

Building a Future of Vaccine Trust Through Transparency and Innovation

Presenter: Yurong Fei-Bloom
Internal Medicine
WVCDC 2026
Mavacamten
2:53

Mavacamten in Symptomatic Adolescent Patients With Obstructive HCM: Results From the Phase 3 Scout-HCM Trial

Presenter: Joseph William Rossano
Cardiology
ACC 2026
Pulmonary
13:35

Pulmonary Embolism in 2026: A Case-Based Journey From Diagnosis to Recovery

Presenter: Stanislav Henkin
Cardiology
ACC 2026
Kardinal:
8:56

Kardinal: A Phase 2 Study of Tonlamarsen For the Treatment of Uncontrolled Hypertension

Presenter: Luke Laffin
Cardiology
ACC 2026
Meet the E
7:26

Meet the Experts: 2025 High Blood Pressure Guideline

Presenter: Keith C. Ferdinand
Cardiology
ACC 2026
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease: Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
Cardiology
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
Cardiology
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
Cardiology
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
Cardiology
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
Cardiology
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients

Presenter: Andreas Goette
Cardiology
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Cardiology
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
Cardiology
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
Cardiology
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Cardiology
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
Cardiology
The import
11:22

The importance of the anterior interface in eye surgery

Presenter: Marie-José Tassignon
Internal Medicine
Haematolog
17:26

Haematology is at the forefront - interview with EHA President

Presenter: Antonio Almeida
Oncology
Overall Su
13:30

Overall Survival Results of KEYNOTE-564

Presenter: Stefan N. Symeonides
Oncology
General as
1:18

General aspects of the ESH2023 Hypertension Guidelines - What are the major changes?

Presenter: Michel Burnier
Cardiology
How shall
1:23

How shall be treat hypertension and look at cardiac risk factors when we consider proper treatment?

Presenter: Konstantinos Tsioufis
Cardiology
How to tre
1:06

How to treat patients optimally with chronic coronary syndromes in 2023?

Presenter: Luis Henrique Gowdak
Overall Su
20:13

Overall Survival Results of KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma

Presenter: David F. McDermott
Oncology
How novel
1:07

How novel AI model may help physicians distinguish and identify prefibrotic primary myelofibrosis from essential thrombocythemia?

Presenter: Andrew Srisuwananukorn
Hematology
The future
1:10

The future of Multiple Myeloma management

Presenter: Xavier Leleu
Hematology
Benefits o
1:01

Benefits of myeloma regimens in the real world fall well short of trials

Presenter: Alissa Visram
Hematology
The prefer
0:57

The preferred treatment of hypertension with RAAS blockade inhibitors

Presenter: Martin Strauss
Cardiology
What clini
1:16

What clinicians should know about the new ESH guideline regarding hypertension in women?

Presenter: Renata Cifkova
Cardiology
How to man
1:00

How to manage isolated systolic hypertension in the young?

Presenter: Paolo Palatini
Cardiology
Blood pres
1:34

Blood pressure monitoring in general and what we can do to encourage people.

Presenter: Neil Poulter
Cardiology
How to man
1:08

How to manage masked and masked uncontrolled hypertension?

Presenter: Paolo Palatini
Cardiology
ESMO 2023
1:13

ESMO 2023 Scientific Chair's welcome and invitation to next year's ESMO Congress

Presenter: Silke Gillessen
Oncology